Breathomics: May it Become an Affordable, New Tool for Early Diagnosis and Screening of Lung Cancer? An Exploratory Study on a Cohort of 60 Patients
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Lung Cancer
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Changes in VOCs peaks in patients with lung cancer vs healthy patients
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Breath analysis examining specific patterns of volatile organic compounds (VOCs) has been demonstrated to be able to discriminate lung cancer (LC) patients from healthy controls (HC). However, the existing technology uses complex, expensive, and low throughput analytical platforms to give an offline response, thus preventing its applicability for mass screening. The reliability of a new portable device to enable rapid, on-site LC diagnosis is tested.
Detailed Description
The breath of patients with histologically proven NSCLC and healthy controls was sampled into Tedlar bags through a Nafion filter and a one-way mouthpiece. The breath samples in the bags were then analyzed by an automated micro portable gas chromatography device developed in-house, which consisted of a thermal desorption tube, thermal injector, separation column, and photoionization detector, as well as other accessories such as pumps, valves, and a helium cartridge. The chromatograms were analyzed by chemometrics and machine learning techniques.
Investigators
Eligibility Criteria
Inclusion Criteria
- •NSCLC histologically proven (for LC group) at any stage of disease
- •non-cancer controls who had negative findings on preoperative chest X-rays/chest CT scan (for HC groups)
Exclusion Criteria
- •Patients who had any history of another type of cancer
- •who had received neoadjuvant chemo/radiotherapy because of the possible unknown effects on cancer metabolism
- •pediatric patients.
Outcomes
Primary Outcomes
Changes in VOCs peaks in patients with lung cancer vs healthy patients
Time Frame: 24 hours
Identify biomarkers able to discriminate between lung cancer patients and healthy controls.